Loading…
RenovoRx, Inc. is projected to rise to $1.10 by 2027, a +28% move from its current price of $0.8653. RNXT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/25/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 26 | $0.8441 | $0.8659 | $0.8883 | +0.07% |
| Jul 27 | $0.8359 | $0.8666 | $0.8983 | +0.14% |
| Jul 28 | $0.8298 | $0.8672 | $0.9063 | +0.22% |
| Jul 29 | $0.8247 | $0.8678 | $0.9132 | +0.29% |
| Jul 30 | $0.8204 | $0.8684 | $0.9193 | +0.36% |
| Jul 31 | $0.8165 | $0.8691 | $0.925 | +0.43% |
| Aug 1 | $0.813 | $0.8697 | $0.9303 | +0.51% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.813 | $0.8697 | $0.9303 | +0.51% |
| Week 2 | $0.7946 | $0.8741 | $0.9615 | +1.02% |
| Week 3 | $0.7818 | $0.8785 | $0.9873 | +1.53% |
| Week 4 | $0.7717 | $0.883 | $1.01 | +2.05% |
| Week 5 | $0.7633 | $0.8875 | $1.03 | +2.56% |
| Week 6 | $0.7563 | $0.892 | $1.05 | +3.08% |
| Week 7 | $0.7501 | $0.8965 | $1.07 | +3.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
RenovoRx, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is gemcitabine, provided through RenovoCath, and it is in Phase III clinical trials for locally advanced pancreatic cancer.
The company was founded in 2009 and is headquartered in Mountain View, California. It operates in the Healthcare sector, pursuing oncology-focused therapies with a targeted approach to cancer treatment.
RNXT is the ticker for RenovoRx, Inc. The stock is currently priced at $0.8653, with a market capitalization of $39.02M, and a market rank of 4365. This places the asset as a smaller-cap biotechnology play within the Healthcare space.
The asset sits in the Healthcare sector and presents a multi-year price outlook that transitions from neutral in 2026 to bullish in following years. The forecast shows 2026 average at $0.8653 with ongoing upward momentum: 2027 avg $1.13, 2028 avg $1.46, 2029 avg $1.61, 2030 avg $1.65, 2031 avg $1.72, 2032 avg $1.85, 2033 avg $2.27, 2034 avg $2.61, 2035 avg $2.77, 2040 avg $4.21, and 2050 avg $7.29, with bullish sentiment indicated for most of the horizon.
The forecast implies notable upside potential with ROI figures rising from 0% in 2026 to 30.1% in 2027, 68.6% in 2028, 85.6% in 2029, 90.2% in 2030, 99.1% in 2031, 113.5% in 2032, 162.4% in 2033, 201.4% in 2034, and 220.7% in 2035, culminating in 386% in 2040 and 742.6% in 2050. The long‑range max forecast reaches $13.66 by 2050, underscoring the potential upside within the modeled outlook.
A major floor 12.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.5% away) — a key level to hold.
The nearest ceiling, 13.3% above — a clean break opens room to run.
A major ceiling 34.1% above — clearing it would confirm fresh momentum.
Key RNXT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RNXT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.8656 | Sell | $0.8663 | Sell |
| MA 10 | $0.8762 | Sell | $0.8776 | Sell |
| MA 20 | $0.9089 | Sell | $0.8911 | Sell |
| MA 50 | $0.8945 | Sell | $0.902 | Sell |
| MA 100 | $0.916 | Sell | $0.9186 | Sell |
| MA 200 | $0.9495 | Sell | $0.9618 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.60 | Neutral |
| Stoch RSI (14) | 13.17 | Buy |
| CCI (20) | -99.54 | Neutral |
| Williams %R (14) | -94.90 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -7.87 | Sell |
| Bollinger %B (20,2) | 0.17 | Neutral |
| Stochastic %K (14) | 5.10 | Buy |
| TRIX (15) | -0.08 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 48.37 | Neutral |
| Momentum (10) | -0.08 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 0.86 | Buy |
| ADX (14) | 10.27 | Neutral |
| ATR (14) | 0.02 | Info |
The near-term technical picture remains NEUTRAL. RSI is 40, with the 14-day RSI below the 50 level that suggests neither overbought nor oversold conditions.
Key moving averages show a gradual convergence toward recent price levels: SMA50 is $0.8949 and SMA200 is $0.9582. Support sits at $0.844 and resistance at $0.98, framing a narrow near-term range alongside a 30-day price range of $0.7181 to $1.04.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.783 | $0.8653 | $1.17 | 0% | Neutral | |
| $0.8861 | $1.10 | $1.45 | +28% | Bullish | |
| $1.10 | $1.41 | $1.92 | +63% | Bullish | |
| $1.18 | $1.54 | $2.16 | +78% | Bullish | |
| $1.21 | $1.61 | $2.30 | +86% | Bullish | |
| $1.24 | $1.68 | $2.45 | +94% | Bullish | |
| $1.29 | $1.78 | $2.65 | +106% | Bullish | |
| $1.56 | $2.18 | $3.30 | +152% | Bullish | |
| $1.75 | $2.48 | $3.82 | +187% | Bullish | |
| $1.83 | $2.63 | $4.10 | +204% | Bullish | |
| $2.59 | $3.96 | $6.55 | +358% | Bullish | |
| $4.06 | $6.90 | $12.43 | +697% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.783 | $0.8653 | $1.02 | +0.00% |
| August 2026 | $0.7533 | $0.8844 | $1.06 | +2.21% |
| September 2026 | $0.7815 | $0.9243 | $1.12 | +4.51% |
| October 2026 | $0.7761 | $0.9234 | $1.13 | -0.10% |
| November 2026 | $0.76 | $0.9088 | $1.12 | -1.58% |
| December 2026 | $0.7793 | $0.9361 | $1.17 | +3.01% |
Click any year to see its month-by-month RNXT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect RNXT to range from $0.783 to $1.17 through 2026. The $0.8653 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The RNXT price prediction for 2027 points to an average of $1.10 (low $0.8861, high $1.45) — a potential gain of +28% on today's $0.8653. Momentum favours further upside here.
In 2028, RNXT is projected to trade between $1.10 and $1.92, averaging $1.41 — a potential gain of +63% from today's $0.8653. That is up +27% on the projected 2027 average. Buyers look set to stay in control over this stretch.
RenovoRx, Inc.'s 2029 outlook centres on $1.54, within a $1.18 to $2.16 range. That is up +10% on the projected 2028 average. That marks a +78% change versus current levels. Momentum favours further upside here.
By 2030, RNXT could reach as high as $2.30, with a base case around $1.61 and support toward $1.21 — roughly +86% from $0.8653. Buyers look set to stay in control over this stretch.
Expect RNXT to range from $1.24 to $2.45 through 2031. The $1.68 average target implies a +94% move from current prices. That is up +4% on the projected 2030 average. Momentum favours further upside here.
The RNXT price prediction for 2032 points to an average of $1.78 (low $1.29, high $2.65) — a potential gain of +106% on today's $0.8653. Buyers look set to stay in control over this stretch.
In 2033, RNXT is projected to trade between $1.56 and $3.30, averaging $2.18 — a potential gain of +152% from today's $0.8653. That is up +22% on the projected 2032 average. Momentum favours further upside here.
RenovoRx, Inc.'s 2034 outlook centres on $2.48, within a $1.75 to $3.82 range. That is up +14% on the projected 2033 average. That marks a +187% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, RNXT could reach as high as $4.10, with a base case around $2.63 and support toward $1.83 — roughly +204% from $0.8653. Momentum favours further upside here.
Expect RNXT to range from $2.59 to $6.55 through 2040. The $3.96 average target implies a +358% move from current prices. That is up +50% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The RNXT price prediction for 2050 points to an average of $6.90 (low $4.06, high $12.43) — a potential gain of +697% on today's $0.8653. Momentum favours further upside here.
Investing $1,000 in RNXT today (≈ 1,155.668554 RNXT) could be worth
$7,972.25
+$6,972.25 (+697%) by 2050 · US Dollar
Based on the average projected RNXT price of $6.9 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RNXTwould be worth at today's price.
$1,000 invested in RNXT on Jul 23, 2025 (≈ 787.401587 RNXT) would be worth
$681.34
-$318.66 (-31.9%) today · 0.68× · US Dollar
Based on a RNXT entry price of $1.27 vs. today's $0.8653.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.881 | $982.18 | -1.8% |
| 1 month ago | $0.911 | $949.84 | -5.0% |
| 3 months ago | $0.857 | $1,009.68 | +1.0% |
| 6 months ago | $0.996 | $868.78 | -13.1% |
| 1 year ago | $1.27 | $681.34 | -31.9% |
| All time (4.9y) ago | $7.26 | $119.19 | -88.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RNXT forecast.
Our base-case forecast reaches $1.70 around 2032.
Implied market cap at $1.70: $76.67M
The multi-year forecast points to a bullish trajectory beginning in 2027, with 2027 avg $1.13 and rising thereafter. The horizon shows continued gains: 2028 avg $1.46, 2029 avg $1.61, 2030 avg $1.65, 2031 avg $1.72, 2032 avg $1.85, 2033 avg $2.27, 2034 avg $2.61, and 2035 avg $2.77; sentiment is listed as BULLISH for these years.
Further out, 2040 is forecast at avg $4.21 with a max of $7.18 and 2050 at avg $7.29 with a max of $13.66. ROI grows from 386% in 2040 to 742.6% in 2050, all with bullish sentiment. These figures are estimates and not guarantees, but they outline a path of sustained upside potential over the horizon.
Tap a question to reveal the answer.
2030 forecast shows min $1.21, avg $1.65, max $2.41 with ROI 90.2% and sentiment BULLISH.
The outlook shows a neutral stance in 2026 (avg $0.8653, ROI 0%) and bullish sentiment from 2027 onward, with rising averages and ROI up to 742.6% by 2050; these are estimates and not guarantees.
Yes, the long-term max forecast reaches $7.18 in 2040, which implies that exceeding $5 is within the forecast horizon.
The short-term picture shows NEUTRAL sentiment, RSI 40, SMA50 $0.8949, SMA200 $0.9582, with support at $0.844 and resistance at $0.98. The 30-day range is $0.7181 to $1.04.
Lead product candidate is gemcitabine provided through RenovoCath, in Phase III clinical trials for locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
RenovoRx, Inc. Community Discussion
0Share your RenovoRx, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.